Last reviewed 2026-05-18 · How we verify

DNR.NPC-specific T cells

Baylor College of Medicine · Phase 1 active Biologic Quality 35/100

DNR.NPC-specific T cells is a Adoptive cell therapy Biologic drug developed by Baylor College of Medicine. It is currently in Phase 1 development.

Autologous T cells engineered to recognize and attack nasopharyngeal carcinoma cells expressing tumor-associated antigens.

Likelihood of approval

9.6% vs 9.6% industry baseline

If approved by FDA: likely 2033–2036

Steps remaining: Phase 2 → Phase 3 → NDA/BLA submission

Confidence: Medium

Why this estimate

Baseline phase 1 → approval rate +9.6pp
Industry-wide phase 1 drugs reach approval ~9.6% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).

Predicted approval windows by jurisdiction (conditional on FDA approval)

Regulator	Country	Likely year	Lag vs FDA
FDA	US	2033–2036	—
EMA	EU	2034–2037	+0.7 yr
MHRA	GB	2034–2037	+0.7 yr
Health Canada	CA	2034–2038	+0.9 yr
TGA	AU	2034–2038	+1.2 yr
PMDA	JP	2034–2038	+1.5 yr
NMPA	CN	2035–2039	+2.3 yr
MFDS	KR	2034–2038	+1.4 yr
CDSCO	IN	2034–2039	+1.8 yr
ANVISA	BR	2035–2039	+2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic name	DNR.NPC-specific T cells
Sponsor	Baylor College of Medicine
Drug class	Adoptive cell therapy
Modality	Biologic
Phase	Phase 1

Mechanism of action

DNR.NPC-specific T cells are generated from a patient's own immune cells and modified to recognize antigens associated with nasopharyngeal carcinoma. These cells are expanded ex vivo and infused back into the patient to mount a targeted immune response against tumor cells.

Approved indications

Common side effects

No common side effects on file.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

DNR.NPC-specific T cells CI brief — competitive landscape report
DNR.NPC-specific T cells updates RSS · CI watch RSS
Baylor College of Medicine portfolio CI

Frequently asked questions about DNR.NPC-specific T cells

What is DNR.NPC-specific T cells?

DNR.NPC-specific T cells is a Adoptive cell therapy drug developed by Baylor College of Medicine.

How does DNR.NPC-specific T cells work?

Autologous T cells engineered to recognize and attack nasopharyngeal carcinoma cells expressing tumor-associated antigens.

Who makes DNR.NPC-specific T cells?

DNR.NPC-specific T cells is developed by Baylor College of Medicine (see full Baylor College of Medicine pipeline at /company/baylor-college-of-medicine).

What drug class is DNR.NPC-specific T cells in?

DNR.NPC-specific T cells belongs to the Adoptive cell therapy class. See all Adoptive cell therapy drugs at /class/adoptive-cell-therapy.

What development phase is DNR.NPC-specific T cells in?

DNR.NPC-specific T cells is in Phase 1.

Drug class: All Adoptive cell therapy drugs
Manufacturer: Baylor College of Medicine — full pipeline

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing